TransEnterix Announces Launch of Underwritten Public Offering

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has commenced an underwritten offering of units. The offering is expected to be comprised of (i) a unit of common stock and warrants to purchase shares of common stock and (ii) a unit of convertible preferred stock and warrants to purchase shares of common stock. The unit of convertible preferred stock and warrants is being offered in lieu of the unit of common stock and warrants for those purchasers who would otherwise beneficially own more than 4.99% (or, at the election of the purchaser 9.99%). The preferred stock to be issued in the offering, if any, includes a beneficial ownership blocker but has no dividend rights (except to extent dividends are also paid on the common stock),voting rights, liquidation preference or other preferences over common stock.